MedPath

A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

Phase 2
Completed
Conditions
Cytomegalovirus Retinitis
HIV Infections
Registration Number
NCT00002156
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Brief Summary

To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.

Detailed Description

In Stage 1 of the study, 20 patients receive one of two doses of ISIS 2922 on days 1, 8, and 15 (Induction) then every 14 days (maintenance), with ganciclovir given daily during both Induction and Maintenance. Escalation to the second dose does not occur until all patients at the first dose level have reached their first maintenance dose (day 29). In Stage 2 of the study, 174 patients are randomized to receive either a) ISIS 2922 at the dose established in Stage 1 on days 1, 8, and 15 and then every 14 days, with ganciclovir given daily during both Induction and Maintenance, or b) ganciclovir daily for 14 consecutive days and then a lower dose as maintenance. Patients may continue to receive ISIS 2922 biweekly if the dose is safe and their CMV retinitis is clinically controlled. Per 2/8/96 amendment, patients are now in Stage 2 at 150 mcg.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
194
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

Univ of Texas Southwestern Med Ctr of Dallas

🇺🇸

Dallas, Texas, United States

Retina - Vitreous Associates Med Group

🇺🇸

Los Angeles, California, United States

Univ of Illinois

🇺🇸

Chicago, Illinois, United States

Dr Julio Perez

🇺🇸

Fort Lauderdale, Florida, United States

Georgia Retina

🇺🇸

Atlanta, Georgia, United States

Indiana Univ Med Ctr

🇺🇸

Indianapolis, Indiana, United States

San Diego Naval Hosp

🇺🇸

San Diego, California, United States

Santa Clara Valley Med Ctr

🇺🇸

San Jose, California, United States

Graduate Hosp

🇺🇸

Philadelphia, Pennsylvania, United States

Vitreo - Retinal Consultants

🇺🇸

New York, New York, United States

Community Eye Med Group

🇺🇸

Pasadena, California, United States

Hahnemann Univ Hosp

🇺🇸

Philadelphia, Pennsylvania, United States

Novum Inc

🇺🇸

Seattle, Washington, United States

Univ of California San Francisco / SF Gen Hosp

🇺🇸

San Francisco, California, United States

Charlotte Eye Ear Nose and Throat Association

🇺🇸

Charlotte, North Carolina, United States

Univ of Colorado Health Sciences Ctr

🇺🇸

Denver, Colorado, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

Virginia Eye Consultants

🇺🇸

Norfolk, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath